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Cell death plays an essential role in the development of tissues and organisms, the etiology of
disease, and the responses of cells to therapeutic drugs. Here we review progress made over
the last decade in using mathematical models and quantitative, often single-cell, data to study
apoptosis. We discuss the delay that follows exposure of cells to prodeath stimuli, control of
mitochondrial outer membrane permeabilization, switch-like activation of effector caspases, and
variability in the timing and probability of death from one cell to the next. Finally, we discuss
challenges facing the fields of biochemical modeling and systems pharmacology.Introduction
Apoptosis is a form of programmed cell death involving
caspases, specialized cysteine proteases found in animal cells
as inactive proenzymes (Fuentes-Prior and Salvesen, 2004).
Dramatic progress has been made in recent years in identifying
and determining the biochemical activities and cellular functions
of biomolecules that regulate apoptosis and carry out its proteo-
lytic program. However, current knowledge is largely qualitative
and descriptive, and the complex circuits that integrate prosur-
vival and prodeath signals to control the fates of normal and
diseased cells remain poorly understood. Successful creation
of quantitative and predictive computational models of
apoptosis would be significant from both basic research and
clinical perspectives. From the standpoint of basic research,
apoptosis is a stereotypical systems-level problem in which
complex circuits involving graded and competing molecular
signals determine binary life-death decisions at a single-cell
level. Progress in modeling such decisions has had a significant
impact on the small but growing field of mammalian systems
biology. From a clinical perspective, diseases such as cancer
involve disruption of the normal balance between cell prolifera-
tion and cell death, and anticancer drugs are thought to achieve
their therapeutic effects by inducing apoptosis in cancer cells
(Fadeel et al., 1999). However, it is difficult to anticipate whether
a tumor cell will or will not be sensitive to a proapoptotic stimulus
or drug based on general knowledge of apoptosis biochemistry
because the importance of specific processes varies dramati-
cally from one cell type to the next. Predictive, multifactorial,
and context-sensitive computational models relevant to disease
states will impact drug discovery and clinical care.
Apoptosis can be triggered by intrinsic and extrinsic stimuli. In
intrinsic apoptosis, the death-inducing stimulus involves cellular
damage or malfunction brought about by stress, ultraviolet (UV)
or ionizing radiation, oncogene activation, toxin exposure, etc.
(Kaufmann and Earnshaw, 2000). Extrinsic apoptosis is triggered
by binding of extracellular ligands to specific transmembrane926 Cell 144, March 18, 2011 ª2011 Elsevier Inc.receptors, primarily members of the tumor necrosis factor
receptor (TNFR) family (Kaufmann and Earnshaw, 2000).
Receptor binding by TNF family ligands activates caspase-
dependent pathways that are quite well understood in molecular
terms. In general, extrinsic apoptosis has received more atten-
tion than intrinsic apoptosis from investigators seeking to
develop mathematical models, but extrinsic and intrinsic
apoptosis share many components and regulatory mechanisms.
The best studied inducers of extrinsic apoptosis are TNF-a,
Fas ligand (FasL, also known as Apo-1/CD95 ligand), and TRAIL
(TNF-related apoptosis-inducing ligand, also known as Apo2L;
Figure 1A). Binding of these ligands to trimers of cognate recep-
tors causes a conformational change that promotes assembly of
death-inducing signaling complexes (DISCs) on receptor cyto-
plasmic tails (Gonzalvez and Ashkenazi, 2010). DISCs contain
multiple adaptor proteins, such as TRADD and FADD, which
recruit and promote the activation of initiator procaspases. The
composition of the DISC differs from one type of death receptor
to the next and also changes upon receptor internalization
(Schutze et al., 2008). A remarkable feature of TNF-family recep-
tors is that they activate both proapoptotic and prosurvival
signaling cascades and the extent of cell death is determined
in part by the balance between these competing signals. Pro-
death processes are triggered by activation of initiator procas-
pases-8 and -10 at the DISC, a process that can be modulated
by the catalytically inactive procaspase-8 homolog FLIP
(Fuentes-Prior and Salvesen, 2004). Prosurvival processes are
generally ascribed to activation of the NF-kB transcription factor,
but other lesswell-understood processes are also involved, such
as induction of themitogen-activated protein kinase (MAPK) and
Akt (protein kinase B) cascades (Falschlehner et al., 2007).
Initiator caspases recruited to the DISC directly cleave effector
procaspases-3 and -7 generating active proteases (Fuentes-
Prior and Salvesen, 2004). Effector caspases cleave essential
structural proteins such as cytokeratins and nuclear lamins
and also inhibitor of caspase-activated DNase (iCAD), which
Figure 1. Modeling Receptor-Mediated Apoptosis
(A) Simplified schematic of receptor-mediated apoptosis signaling, with
fluorescent reporters for initiator caspases (IC FRET) and effector caspases
(EC FRET) indicated. The MOMP reporter measures mitochondrial outer
membrane permeablization.
(B) Steps involved in converting a biochemical cartoon into a reaction diagram
and ordinary differential equations. C8* indicates active caspase-8.
Lower panels show a model-based 12 hr simulation of the increase in tBid
relative to the time of MOMP and analysis of the sensitivity of MOMP time to
Bid levels. The simulation in (B) was adapted from Albeck et al. (2008b).liberates the DNase (CAD) to digest chromosomal DNA and
cause cell death. So-called ‘‘type I’’ apoptosis, which comprises
a direct pathway of receptor/initiator caspases/effector cas-
pases/death, is thought to be sufficient for death in certain cell
types, but in most cell types apoptosis occurs by a ‘‘type II’’
pathway in which mitochondrial outer membrane permeabiliza-
tion (MOMP) is a necessary precursor to effector caspase activa-
tion (Scaffidi et al., 1998). MOMP is triggered by the formation of
pores in the mitochondrial membrane. Pore formation is
controlled by the20members of the Bcl-2 protein family, which
can be roughly divided into four types: the ‘‘effectors’’ Bax and
Bak whose oligomerization creates pores; ‘‘inhibitors’’ of Bax
and Bak association such as Bcl-2, Mcl1, and BclxL; ‘‘activa-
tors’’ of Bax and Bak such as Bid and Bim; and ‘‘sensitizers’’
such as Bad, Bik, and Noxa that antagonize antiapoptotic Bcl-
2-like proteins (Letai, 2008). In extrinsic apoptosis, initiator cas-
pases that have been activated at the DISC cleave Bid into tBid,
which in turn promotes a conformational change in Bax and Bak
leading to oligomerization. Bax or Bak oligomers create pores in
the mitochondrial outer membrane and promote cytoplasmic
translocation of critical apoptosis regulators such as cytochrome
c and Smac/Diablo, which normally reside in the space between
the outer and inner mitochondrial membranes. MOMP does not
occur until proapoptotic pore-forming proteins overwhelm antia-
poptotic Bcl-2-like proteins (the so-called rheostat model) (Kors-
meyer et al., 1993). Under most circumstances, MOMP is
a sudden process that lasts a few minutes and marks the point
of no return in the commitment to cell death (Chipuk et al.,
2006; Tait et al., 2010). Once translocated to the cytosol, cyto-
chrome c combines with Apaf-1 and caspase-9 to form the
apoptosome, which cleaves and activates effector procaspases
(Fuentes-Prior and Salvesen, 2004). XIAP associates with the
catalytic pocket of active effector caspases-3 and -7 blocking
protease activity and promoting their ubiquitin-dependent
degradation. Binding of Smac to XIAP relieves this inhibition, al-
lowing effector caspases to cleave their substrates and cause
cell death (Fuentes-Prior and Salvesen, 2004).
In this Review, we describe how combining theoretical and
computational approaches with live-cell imaging and quantita-
tive biochemical analysis has provided new insight into mecha-
nisms controlling the dynamics of extrinsic apoptosis. We start
with a brief description of modeling concepts and methods rele-
vant to apoptosis research. Next, we survey the recent literature.
Modeling apoptosis, like quantitative analysis of mammalian
signal transduction in general, is a field in its infancy fraught
with many technical and conceptual challenges. Thus, only
a subset of the known biochemistry of extrinsic apoptosis has
been subjected to computational analysis, and this analysis
has been performed only in a few cell lines. Key questions,
such as differences between normal and transformed cells,
have not yet been addressed in terms amenable to modeling.
This Review, therefore, focuses on the subset of questions for
which modeling has provided new insight (Figure 2). These
include: (1) How is all-or-none control over effector caspase
activity achieved? (2) How are activated effector caspases in-
hibited during the pre-MOMP delay while initiator caspase
activity rises? (3) How do prosurvival and prodeath signals
interact to determine if and when MOMP occurs? (4) WhatCell 144, March 18, 2011 ª2011 Elsevier Inc. 927
causes cell-to-cell variation in the timing and probability of
apoptosis? We close this Review with an evaluation of current
and emerging methods and future prospects. Readers inter-
ested in a more thorough description of the biology of extrinsic
apoptosis are referred to several excellent reviews (Fuentes-
Prior and Salvesen, 2004; Gonzalvez and Ashkenazi, 2010;
Hengartner, 2000) and to Douglas Green’s new book Means to
an End: Apoptosis and Other Cell Death Mechanisms (Green,
2011).
Modeling Concepts Relevant for Apoptosis
The term ‘‘model’’ is used in a variety of fields in the natural and
applied sciences to describe a mathematical or computational
representation of a physical system. In molecular biology, the
term usually refers to a ‘‘word model’’ or narrative description
accompanied by a diagram, although it can also refer to a cell
line or genetically engineered mouse that recapitulates aspects
of a human disease. In this Review, we restrict use of the term
‘‘model’’ to describe an executable set of rules or equations in
mathematical form. We are primarily interested in models that
are built and tested using detailed cellular or biochemical exper-
iments. Models of cellular biochemistry can be based on
different mathematical formalisms, from Boolean logic to differ-
ential equations, depending on the degree of detail and the
scope of the modeling effort. Most models of apoptosis have
been encoded using ordinary differential equations (ODEs),
which describe the evolution of a system in continuous time.
ODEs are the mathematical representation of mass action
kinetics, the familiar biochemical approximation in which rates
of reaction are proportional to the concentrations of reactants
(Figure 1B) (Chen et al., 2010). Diffusion, spatial gradients, or
transport can be modeled explicitly using partial differential
equations (PDEs), which represent biochemical systems in
continuous time and space. For example, Rehm et al. (2009)
used PDEs to model the spread of mitochondrial permeabiliza-
tion through a cell following an initial, localized MOMP event.
Using sets of differential equations it is possible to encode
a complex network of interacting biochemical reactions and
then study network dynamics under the assumption that protein
concentrations and reaction rates can be estimated from exper-
imental data. Differential equation models often increase rapidly
in complexity as species are added, as each new protein can
give rise to a large number of model species differing in location,
binding state, and degree of posttranslational modification. This
problem has effectively limited data-dependent ODE/PDE
models to fewer than 20 gene products (and on the order of
50–100 model species), although efforts are underway to
increase this limit.
In addition to differential equations, several other formalisms
have been used to model apoptosis. Stochastic models make
it possible to represent reactions as processes that are discrete
and random, rather than continuous and deterministic.
Stochastic models are advantageous when the number of indi-
vidual reactants of any species is small (typically fewer than
100) or reaction rates very slow (Zheng and Ross, 1991). In
these cases, a Monte Carlo procedure is used to represent the
probabilistic nature of collisions and reactions among individual
molecules (Gillespie, 1977). For example, stochastic cellular au-928 Cell 144, March 18, 2011 ª2011 Elsevier Inc.tomata have been used to model the movement of molecules on
the mitochondrial outer membrane (Chen et al., 2007). When
sufficient time-resolved quantitative data are lacking, a less
precise modeling framework is usually advantageous, and
logic-based models have proven particularly popular. Boolean
models, for example, are discrete two-state logical models in
which each node in a network is represented as a simple on/
off switch. Boolean models have been used to represent the
interplay among survival, necrosis, and apoptosis pathways
and to predict the likelihood that each phenotype would result
following changes in the levels of regulatory proteins (Calzone
et al., 2010). However, the more qualitative and phenomenolog-
ical the modeling framework, the less mechanistic the insight.
Regardless of modeling framework, a trade-off exists between
model tractability and model detail or scope. The inclusion of
morespeciesmakes it possible toanalyzebiochemicalprocesses
in greater detail or to represent the operation of large networks
involvingmanygeneproducts, but largermodelsaremoredifficult
to constrain with experimental data, and excess detail can mask
underlying regulatory mechanisms. A Jorge Luis Borges story
comes to mind in which the art of cartography achieved such
aperfection of detail that cartographersbuilt amapof their empire
with 1:1 correspondence to the empire itself, rendering the map
useless (Borges and Hurley, 1999). On the other hand, although
small models have the advantage of relative simplicity and even
analytical tractability (i.e., capable of being solved exactlywithout
simulation), they run the risk of grossly simplifying the underlying
biochemistry and of including an insufficient number of regulatory
processes. As yet, no clear principles exist to guide decisions
about model scope and complexity, and most studies remain
constrained by the relative immaturity of modeling software and
a paucity of experimental data.
Estimating values for rate constants and initial protein concen-
trations (the parameters in differential equation models) remains
extremely challenging both computationally and experimentally.
Each reaction in an ODE model is associated with one or more
‘‘initial conditions’’ (the concentrations of reactants at time
zero) and rate constants, usually a forward and reverse rate
constant. Some of these parameters are available in the litera-
ture, typically from in vitro biochemical experiments, and these
valuesmay hold true in the context of a cell. In many other cases,
however, no estimates of rate constants are available and
parameters must be estimated directly from experiments
(Chen et al., 2010). In addition, protein concentrations vary
from cell type to cell type and should be measured directly in
the cell type under investigation, although this is often not
done because it is time consuming. The estimation of unknown
parameter values based on data (typically, time-dependent
changes in the abundance or localization of proteins in the
model) is called model calibration, model training, or model
fitting. Almost all realistic models of biological systems are too
large for all parameters to be fully constrained by experimental
data, and the models are therefore ‘‘nonidentifiable.’’ Thus far,
the process of model calibration has been approached rather
informally, but more rigorous approaches are in development
(e.g., Kim et al., 2010). Careful analysis is expected to confirm
the common-sense view that solid conclusions can be reached
even in the case of partial knowledge.
Figure 2. Questions Addressed in This
Review
(A and B) Composite plot of effector caspase
substrate cleavage measured using a CFP-
DEVDR-YFP reporter (A) or initiator caspase
substrate cleavage measured using CFP-IETDG-
GIETD-YFP (B) for >50 HeLa cells treated with
50 ng/ml TRAIL in the presence of cycloheximide
and aligned by the average time of MOMP (red
line).
(C) Fitted trajectories for initiator caspase
substrate cleavage (assayed using CFP-IETDG-
GIETD-YFP) in single HeLa cells treated with
10 ng/ml TRAIL in the presence of cycloheximide
(fits are based on sampling at 3 min intervals).
Concomitant expression of a reporter for MOMP
permits a determination of the time at which
mitochondria permeabilize and thus an estimation
of the height of the MOMP threshold (yellow
circles) and the rate of approach to the threshold
(the ‘‘slope’’ of the green lines).
(D) Histograms of time of death in HeLa cells
treated with various death ligands in the presence
of cycloheximide, as determined by live-cell
microscopy.
(A), (B), and (D) were adapted from Albeck et al.
(2008b); (C) was adapted from Spencer et al.
(2009).Modeling biological processes requires the collection and
analysis of quantitative experimental data. An ODEmodel, which
assumes that each compartment is well mixed, necessarily
represents a single cell, and calibrating and testing ODE models
therefore require collecting data on single cells over time.
However, live-cell imaging experiments usually rely on geneti-
cally modified cell lines carrying fluorescent reporters. Creating
these lines is relatively time-consuming, and the extent of multi-
plexing is limited by phototoxicity and the availability of noninter-
fering fluorophores. It is not always clear that an engineered
reporter correctly represents the activity or state of modification
of endogenous proteins (see, for example, discrepancies
regarding initiator caspase activity reporters, discussed below;
Albeck et al., 2008a; Hellwig et al., 2008; Hellwig et al., 2010).
Flow cytometry, immunofluorescence, and single-cell PCR are
also effective means to assay single cells, and biochemical
experiments (immunoblotting or ELISAs for example) performed
on populations of cells remain essential for quantitative biology.
Although rarely addressed, effective integration of data arising
frommultiple measurement methods is an area in which compu-
tational models are likely to play a key role (Albeck et al., 2006).
The construction and parameterization of even a well
designed model do not lead directly to a better understanding
of the system—model analysis is required. The dependence of
the system on parameter values is of particular interest and
can be approached using sensitivity analysis. Sensitivity analysis
involves systematically varying parameters (initial conditions or
rate constants) while monitoring the consequences for model
output (the time at which a cell undergoes apoptosis, for
example). Sensitivity analysis reveals which outputs are sensitive
to variation in which parameters and can be viewed as thecomputational equivalent of experiments that knock down or
overexpress proteins while monitoring phenotype. For example,
Hua et al. (2005) created an ODEmodel of Fas signaling and per-
formed sensitivity analysis by varying the initial concentration of
each protein species 10- or 100-fold above or below a baseline
value. Using the half-time of caspase-3 activation as an output,
they predicted (and confirmed experimentally) that increases
but not decreases in Bcl-2 levels would alter sensitivity to
FasL. From a practical perspective, sensitive parameters must
be estimated with particular care if a model is to be reliable,
but from a biological perspective, they represent possible means
of regulation. Points in a network that exhibit extreme sensitivity
to small perturbations are often referred to as ‘‘fragile’’ (the
converse of ‘‘robust’’), and considerable interest exists in the
idea that fragility analysis, a concept borrowed from control
theory, might be applied to biological pathways. In this view,
fragile points might identify processes frequently mutated in
disease or potentially modifiable using therapeutic drugs (Luan
et al., 2007).
Stability analysis is another commonly used method of model
analysis. Some models of biochemical networks have the inter-
esting property of converging at equilibrium to a small set of
stable states known as fixed points, where the rate of change
in the concentrations of all model species is zero. Identification
and characterization of fixed points can provide valuable insight
into the dynamics of a system, its responses to perturbation, and
the nature of regulatory mechanisms. Of particular interest in
biology is bistability, a property in which a system of equations
has two stable fixed points separated by an unstable fixed point.
Bistability has obvious appeal in the case of apoptosis, in which
cells are either alive or dead, and has been proposed to underlieCell 144, March 18, 2011 ª2011 Elsevier Inc. 929
a variety of binary fate decisions such as maturation of Xenopus
oocytes (Ferrell and Machleder, 1998) and lactose utilization in
E. coli (Ozbudak et al., 2004). From the perspective of control,
many bistable systems have two valuable properties: (1) they
are insensitive to minor perturbations because the system is ‘‘at-
tracted’’ to the nearest stable state (in apoptosis, a bistable
system would be resistant to spontaneous activation of proa-
poptotic proteins, for example), and (2) they exhibit ‘‘all-or-
none’’ transitions from one stable state to another in response
to small changes in the level of a key regulatory input (a property
known in biochemistry as ‘‘ultrasensitivity’’). Bistable processes
often exhibit hysteresis (path dependence): once in the on state,
they do not readily slip back to off. It is often assumed that the
regulatory machinery for apoptosis must be bistable in the math-
ematical sense with one equilibrium state corresponding to cas-
pases off and ‘‘alive’’ and the other to caspases on and ‘‘dead’’
(Figure 3A). Although bistability remains the favorite framework
for thinking about the switch between life and death, bistability
is not strictly necessary for a switch-like transition between
two distinct states (Albeck et al., 2008b). A monostable system
in which the landscape changes through time can create
a temporal switch between two states; in this case, the change
in the landscape involves the creation, destruction, or transloca-
tion of precisely those proteins (caspases, cytochrome c, etc.)
that are known to regulate apoptosis. In this regard, it should
be noted that the ‘‘sharpness’’ of a switch in a conventional bi-
stable system refers to the steepness of the dose-response
curve (to a change in the concentration of a regulatory protein,
for example), not necessarily sharpness in time. In contrast,
the ‘‘all-or-nothing’’ switch observed by time-lapse microscopy
of cells undergoing apoptosis refers to a switch from alive to
dead that is sharp in a temporal sense. These considerations
do not imply that the biochemical pathways controlling
apoptosis are not bistable systems, but rather that bistability is
not necessary a priori.
Modeling and Measuring Receptor-Mediated Apoptosis
The first model of extrinsic apoptosis was published a decade
ago and set the stage for subsequent work in the field. Fusse-
negger et al. (2000) used emerging understanding of MOMP
and caspase activation by death receptors to assemble a simple
ODE model. By increasing or decreasing the levels of pairs of
proteins in the model, the authors determined which combina-
tions promoted or blocked effector caspase activation, thereby
providing insight into ratiometric control over cell death by cas-
pase-3 and XIAP (Fussenegger et al., 2000). At the same time,
the development of fluorescent reporters for MOMP and cas-
pase substrate cleavage allowed several groups to collect data
on the dynamics of apoptosis in single cells. These data showed
that following exposure to inducers of either intrinsic or extrinsic
apoptosis (UV light, actinomycin D, staurosporine, or TNF), cells
wait for several hours before initiating a rapid chain of events that
triggers MOMP and activates effector caspases (Goldstein et al.,
2000a, 2000b; Tyas et al., 2000). This contrasts with data ob-
tained by western blotting and other population-average
biochemical assays that suggested that MOMP and caspase
activation occur gradually over a period of several hours. The
two types of data can be reconciled by noting that apoptosis is930 Cell 144, March 18, 2011 ª2011 Elsevier Inc.sudden and switch like in individual cells, but that it takes place
at different times in different cells (Figure 3B) (Goldstein et al.,
2000a; Goldstein et al., 2000b; Tyas et al., 2000).
All-or-None Control over Effector Caspase Activity
Goldstein et al. (2000b) used time-lapse imaging of cytochrome
c translocation to obtain the first data on the kinetics of MOMP.
They observed the time between proapoptotic insult and MOMP
to vary depending on the type and strength of the stimulus
(ranging from 4–20 hr following exposure to the pan-specific
kinase inhibitor staurosporine and 9–17 hr following exposure
to UV light), but the rate and extent of cytochrome c release
were constant, taking 5 min to reach completion. Further
understanding of the link between MOMP and caspase activa-
tion was made possible by the development of intramolecular
Fo¨rster resonance energy transfer (FRET) reporters for cas-
pase-mediated proteolysis. The first FRET reporters for moni-
toring caspase activity by time-lapse microscopy linked cyan
fluorescent protein (CFP) to yellow fluorescent protein (YFP)
using a polypeptide linker containing the amino acid sequence
DEVD, a substrate for caspase-3 (CFP-DEVD-YFP) (Rehm
et al., 2002; Tyas et al., 2000). Prior to reporter cleavage, CFP
lies in close proximity to YFP, causing FRET between the two
fluorescent proteins and reducing CFP emission. Following
cleavage of the DEVD-containing linker, the efficiency of FRET
drops dramatically, increasing the CFP to YFP fluorescence
ratio. Time-lapse imaging of cells expressing CFP-DEVD-YFP
revealed that caspase-3 is also activated rapidly, taking
<15 min to reach completion (Rehm et al., 2002; Tyas et al.,
2000).
Rehm et al. (2002) asked whether the cleavage kinetics of
effector caspase substrates depended on the identity or
strength of the apoptotic stimulus. Like Goldstein et al.
(2000b), Rehm and colleagues observed the delay between
exposure to a prodeath stimulus and the onset of effector cas-
pase activation to vary from cell to cell. They also noted that
the average delay varied with the dose and identity of the proa-
poptotic stimulus (3 ng/ml or 200 ng/ml TNF, 3 mMstaurosporine,
10 mM etoposide), but the kinetics of reporter cleavage did not.
The authors developed a quantitative description of these
data, showing that caspase activation in individual cells fits
a sigmoidal Boltzmann equation in which the lag time is dose
and stimulus dependent, but cleavage kinetics are dose invariant
(Figures 3C and 3D) (Rehm et al., 2002). Subsequent multiplex
imaging of MOMP and effector caspase reporters in single cells
showed that MOMP precedes effector caspase activation by
10 min (Rehm et al., 2003). In electromechanical terminology,
the regulation ofMOMPand effector caspase activity constitutes
a variable delay, snap-action switch.
Intrigued by the idea that a switch is central to the regulation of
apoptosis, several groups have attempted to understand how
such a switch might arise, based on models in which bistability
is assumed as a design principle. Eissing et al. (2004) created
an 8-equation ODE model of apoptosis in a type I cell that
included activation of caspase-8, consequent cleavage and
activation of caspase-3, inhibition and degradation of activated
caspase-3 by XIAP, and activation of residual caspase-8 by acti-
vated caspase-3 in a feedback loop. The small size of the model
made it possible to identify stable states analytically, and the
authors found that adding a mechanism to inhibit active cas-
pase-8 (via the protein Bar) was necessary to ensure bistability
at the level of effector caspase activity (Eissing et al., 2004).
A subsequent modeling study that examined how cells would
resist spontaneous procaspase-8 activation argued against
a major role for Bar, however (Wurstle et al., 2010). Legewie
et al. (2006) created a 13-ODE model that described activation
of caspase-9 by Apaf-1, consequent activation of caspase-3,
and inhibition of caspases by XIAP. The authors identified an
‘‘implicit’’ or hidden positive feedback loop as a key contributor
to bistability; in this loop, caspase-3 promotes its own activation
by sequestering XIAP away from caspase-9, allowing caspase-9
to cleave additional procaspase-3 (Legewie et al., 2006). Bagci
et al. (2006) built models of varying complexity (the largest being
31 ODEs) centered on apoptosome formation and caspase-3
activation and concluded that cooperativity in the formation of
the apoptosomewas a key element for ensuring bistability (Bagci
et al., 2006). Chen et al. (2007) constructed both an ODE model
and a stochastic cellular automatonmodel to examine the poten-
tial for interactions among Bcl-2-family members to generate
bistability at MOMP. These models included activation of Bax
by an activator such as tBid, inhibition of the activator and Bax
by Bcl-2, and displacement of the activator in the activator-
Bcl-2 complex by Bax. This description of Bax and Bcl-2 also
encoded an implicit positive feedback loop in which freed acti-
vator could bind more Bax, leading to bistability in pore forma-
tion. Addition of cooperativity in Bax multimerization resulted in
a model encoding a one-way (as opposed to bidirectional or
hysteretic) switch (Chen et al., 2007). In a corroborating study
that used flow cytometry, an antibody against activated Bax
(clone 6A7) revealed a bimodal distribution in the staining of
HeLa cells treated with 400 nM staurosporine for 6 hr (Sun
et al., 2010). However, antibody staining is unreliable in dying/
dead cells, so proving the point will require showing bimodality
in Bax activation in cells that have not yet undergone effector
caspase activation. Most recently, Ho andHarrington (2010) built
a small ODE model in which FasL acts as a clustering agent for
Fas receptors. The reactions described spontaneous receptor
opening and closing, constitutive destabilization of open recep-
tors, and ligand-independent and -dependent stabilization of
receptor clusters. Analytical methods showed the system to
exhibit reversible bistability (hysteresis) at low receptor concen-
trations but irreversible bistability at higher local receptor densi-
ties (Ho and Harrington, 2010). In summary, this set of papers
reveals that almost every point in the apoptosis pathway has
the potential to generate bistability in the mathematical sense.
However, many of the papers were written in an era in which it
was not yet common for mathematical modeling to be combined
with quantitative experimentation in a single manuscript. The
results of simulation were compared to data from the literature,
but proposed regulatory mechanisms were not confirmed using
RNAi or other perturbation-based experiments.
Whereas the first generation of apoptosis models focused on
specific steps in the process of cell death (MOMP, apoptosome
formation, etc.), Albeck et al. (2008b) built a model that spanned
the entire pathway of extrinsic apoptosis from ligand binding to
cleavage of effector caspase substrates, albeit in simplified
form. Amodel comprising 58 differential equations was sufficientto capture the essence of TRAIL-receptor binding, cleavage of
initiator and effector caspases, initiation of MOMP, release of
Smac and cytochrome c into the cytoplasm, and finally cas-
pase-3 activation and substrate cleavage. The model was
trained against experimental data that included live-cell micros-
copy, immunoblotting, and flow cytometry in wild-type HeLa
cells or cells perturbed by protein overexpression or RNAi-medi-
ated protein depletion. Model analysis and experiments
confirmed earlier evidence that MOMP is the point in receptor-
mediated apoptosis at which upstream signals are transformed
into an all-or-none snap-action signal (Goldstein et al., 2005,
2000b; Madesh et al., 2002; Rehm et al., 2003; von Ahsen
et al., 2000). To understand how this switchmight work inmolec-
ular terms, Albeck et al. (2008b) analyzed a series of models of
increasing complexity and biochemical realism that linked tBid
cleavage by initiator caspases to Smac/cytochrome c release.
The performance of each model was analyzed for its ability to
create a variable-delay, snap-action switch. A useful insight
was that the ‘‘rheostat model’’ (Korsmeyer et al., 1993), in which
it was postulated that MOMP is triggered when levels of active
Bax/Bak exceed those of Bcl-2/BclxL, only functioned in its
simplest form as a switch if Bax and Bcl-2 were assumed to
associate irreversibly at a rate faster than diffusion. In contrast,
snap-action switching emerged naturally from the biochemistry
of Bax and Bcl-2 if more complex reaction topologies were
assumed; these included slow activation of Bax by tBid, parti-
tioning of reactants into cytosolic and mitochondrial compart-
ments, and a requirement for Bax multimerization. Rapid and
complete translocation of Smac and cytochrome c was ensured
in part by the favorable kinetics of moving proteins down a steep
concentration gradient from the mitochondrion (where they are
abundant) to the cytosol (where they are initially absent). Despite
the apparent success of the Albeck et al. (2008b) model, it is
important to realize that it involves a simple picture of DISC
formation as well as a simplified version of MOMP that lacks
the multiplicity of positive- and negative-acting Bcl-2-family
members present in real cells.
Inhibition of Effector Caspases during
the Pre-MOMP Delay
Better understanding of caspase substrate specificity (Luo et al.,
2003; Stennicke et al., 2000; Thornberry et al., 1997) along with
a direct comparison of CFP-DEVD-YFP cleavage kinetics with
those of endogenous substrates (Albeck et al., 2008a) made
clear that the CFP-DEVD-YFP biosensor is processed by both
effector and initiator caspases. Changing the biosensor linker
to DEVDR made it 20-fold more selective for caspase-3 relative
to caspase-8 (Albeck et al., 2008a), and changing the cleavage
recognition site to IETD resulted in a FRET reporter selective
for initiator caspases (Luo et al., 2003). Combining this selective
effector caspase reporter with a MOMP reporter showed that
effector caspase activity is negligible during the pre-MOMP
delay (Albeck et al., 2008a); this had correctly been assumed
to be true by Rehm et al. (2002), despite the use of a less specific
CFP-DEVD-YFP reporter. In contrast, initiator caspases are
active throughout the pre-MOMP delay (Albeck et al., 2008a;
Hellwig et al., 2008), and their substrates Bid and procaspase-
3 accumulate in cleaved form. Caspase-3 is a very potent
enzyme, and model-based simulation and experiments suggestCell 144, March 18, 2011 ª2011 Elsevier Inc. 931
Figure 3. Using Models to Understand Data
(A) Energy landscape showing frameworks for
achieving two distinct states. Left: A bistable
system has two stable steady states for all time
(once equilibrium is reached), corresponding to
alive and dead. Right: A monostable system starts
with a single stable ‘‘alive’’ state; once the model
starts to evolve, the landscapemorphs as proteins
are created and destroyed, producing a single
stable ‘‘dead’’ state at late times. Making the
transition unidirectional requires processes such
as a threshold.
(B) Top: Immunoblot analysis of PARP cleavage in
HeLa cells treated with 10 ng/ml TRAIL in the
presence of cycloheximide; PARP is an effector
caspase substrate. Bottom: Simulation of the time
course of effector caspase (EC) substrate
cleavage in individual cells (blue lines), overlaid
with an average (pink line) that depicts the fraction
of cells in which caspases have been activated;
this average mimics the data obtained by immu-
noblotting.
(C) Idealized single-cell time course for effector
caspase substrate cleavage. The dynamics have
the form of a sigmoidal Boltzmann equation in
which c(t) is the amount of substrate cleaved at
time t, f is the fraction cleaved at the end of the
reaction, Td is the delay period between TRAIL
addition and half-maximal substrate cleavage,
and Ts is the switching time between initial and
complete effector caspase substrate cleavage
(the reciprocal of the slope at t = Td).
(D) Effector caspase substrate cleavage in indi-
vidual HeLa D98 cells expressing myc-CFP-
DEVD-YFP in response to the indicated doses of
TNF. Data from each cell have been fit with the
sigmoidal Boltzmann function.
(E) Simulation showing effector caspase substrate
cleavage as a function of XIAP concentration. At
high concentrations, effector caspase substrate
cleavage is blocked; at low concentrations,
effector caspases are activated rapidly; and
at concentrations of XIAP between 0.15 and
0.30 mM, effector caspase substrate cleavage
proceeds slowly and only reaches submaximal
levels.
(F) A simulation showing how the initial concen-
trations of procaspase-8 and cFLIPL determine
whether NF-kB is activated, effector caspases are activated, or both after Fas stimulation. The white circle indicates the estimated level of procaspase-8 and
cFLIPL in HeLa-CD95 cells.
(A) and (C) were adapted from Albeck et al. (2008b); (D) was adapted with permission from Rehm et al. (2002), J. Biol. Chem. 277, 24506–24514, copyright 2002
The American Society for Biochemistry and Molecular Biology. All rights reserved; (E) was adapted from Rehm et al. (2006) by permission from Macmillan
Publishers Ltd: EMBO J. 25, 4338–4349, copyright 2006. (F) was adapted from Neumann et al. (2010) by permission from Macmillan Publishers Ltd: Mol. Syst.
Biol. 6, 352, copyright 2010.that 400 active molecules are sufficient to cleave 106–107
molecules of cellular substrate within several hours (Albeck
et al., 2008a). However, during the pre-MOMP delay, no pro-
cessing of effector caspase substrates can be detected using
live-cell FRET reporters or flow cytometry (c.f. Figures 2A and
2B). This raises the interesting question: How are effector cas-
pases maintained in an off state despite being continually pro-
cessed by initiator caspases from a zymogen into a cleaved
and potentially active form?
One mechanism for keeping processed effector caspases
‘‘off’’ is binding of XIAP to the catalytic cleft of caspase-3. This
tight interaction (1 nM) might seem sufficient to hold caspase-
3 in check, but modeling shows that a >100-fold molar excess
of XIAP over caspase-3 would be required to ensure effective932 Cell 144, March 18, 2011 ª2011 Elsevier Inc.inhibition of caspase-3 proteolytic activity over the course of
a typical 2–6 hr pre-MOMP delay. The requirement for such
a large excess of XIAP over caspase-3 arises because competi-
tive inhibition is reversible whereas substrate cleavage is not and
because substrates, which are abundant, are in competition with
XIAP for access to the caspase catalytic site. As XIAP and cas-
pase-3 are present at roughly equal concentrations in HeLa cells,
simple competitive inhibition cannot be the sole inhibitory mech-
anism. XIAP is an E3 ligase able to promote ubiquitination and
degradation of caspase-3, and simulation suggests that a combi-
nation of competitive inhibition and caspase degradation would
constitute an effective means of regulation (Albeck et al., 2008a).
Confirming these predictions, depletion of XIAP by RNAi or phar-
macological inhibition of the proteasome was observed to cause
effector caspase activation prior to MOMP (Albeck et al., 2008a).
Deletion of XIAP in the mouse or truncation of the ubiquitination-
promotingRINGdomain also caused elevated caspase-3 activity
and sensitivity to apoptosis (Schile et al., 2008), demonstrating
a critical role for XIAP-mediated ubiquitination of caspase-3
in vivo. The pre-MOMP delay evidently constitutes a ‘‘latent’’
death state inwhich effector procaspases are actively processed
by initiators but are held in check by XIAP until Smac is released
during MOMP. The reasoning that led to this conclusion illus-
trates the value of making models explicit and analyzing them
computationally: a biochemical mechanism that seems
adequate on its face (Bcl-2-Bax binding in the rheostat model
or competitive inhibition of C3 by XIAP during the pre-MOMP
delay) proves insufficient when actual protein levels and rates
of reaction are taken into account. In this sense, quantitative anal-
ysis can fundamentally change our qualitative understanding of
a regulatory mechanism. It should be noted, however, that
current models of receptor-mediated apoptosis in type II cells
cannot completely restrain pre-MOMP caspase-3 activity when
experimentally measured procaspase-3 and XIAP concentra-
tions are used. Although XIAP-mediated degradation of active
caspase-3 is necessary, raising this degradation rate too much
compromises the switch-like activation of effector caspase
substrate cleavage post-MOMP. Reconciliation of all experi-
mental observations awaits the development of more sophisti-
cated and complete models.
If XIAP is partially depleted by RNAi and MOMP is blocked by
overexpression of Bcl-2, a sublethal level of effector caspase
activity is generated and effector caspase substrates are only
partially processed; moreover incomplete cleavage of cas-
pase-3 substrates does not necessarily cause cell death (at least
in HeLa cells) (Albeck et al., 2008a). Modeling and experiments
with XIAP overexpression suggest three possible outcomes de-
pending on XIAP levels: with [XIAP] < 0.15 mM, effector caspase
substrate cleavage is complete; at [XIAP] > 0.30 mM, cleavage is
fully inhibited; and at intermediate XIAP concentrations, slow
submaximal effector caspase substrate cleavage occurs
(Figure 3E) (Rehm et al., 2006). Thus, alteration of XIAP levels
disrupts normal switch-like control over effector caspase activa-
tion and interferes with the normal link between caspase activa-
tion and cell killing. Activation of CAD in the absence of cell death
is expected to be particularly problematic since it has the poten-
tial to cause genomic instability (Lovric and Hawkins, 2010) and
has been proposed to be the trigger of the chromosomal trans-
locations observed in some leukemias (Betti et al., 2005;
Vaughan et al., 2002, 2005; Villalobos et al., 2006).
The role of XIAP in restraining caspase-3 in the absence of
MOMP makes it a central factor in controlling type I versus
type II apoptosis. Jost et al. (2009) observed that inhibition of
XIAP function by gene targeting or a Smac mimetic drug caused
type II cells to adopt a type I phenotype. Bid deficiency protected
hepatocytes and pancreatic b cells from FasL-induced
apoptosis (fulfilling the definition of mitochondria-dependent
type II death), but concomitant loss of XIAP (in Bid/ XIAP/
mice) restored FasL sensitivity, thereby demonstrating a switch
to type I behavior (Jost et al., 2009). Type I cells are defined as
not requiring MOMP for apoptosis, but blockade of the mito-
chondrial pathway via Bid depletion or Bcl-2 overexpression intype I cells has been observed to reduce effector caspase
activity and to increase the number of cells surviving TRAIL
exposure (Maas et al., 2010). Both type I and type II pathways,
therefore, appear to depend to a greater or lesser extent on
the mitochondrial pathway, either for regulating XIAP and acti-
vating effector caspases or for killing cells by disrupting essential
mitochondrial functions.
Determinants of the Timing and Probability of MOMP
Apoptosis proceeds at different rates in different cells, even
among members of a clonal population. Some cells die within
45 min of exposure to FasL or TRAIL, whereas other cells in
the same dish wait 12 hr or more. A simple way to conceptualize
control over the timing of apoptosis in single cells is that the level
of active receptor determines the amount of active caspase-8/
10, which sets the rate of tBid cleavage and, thus, the rate of
approach to a threshold that must be overcome for MOMP to
occur (Figure 2C). The height of this threshold is set by the rela-
tive levels of competing pro- and antiapoptotic Bcl-2-family
proteins (Chipuk and Green, 2008). We discuss below recent
advances in our understanding of the MOMP threshold and re-
turn later to the determinants of the rate of approach to the
threshold. Using fluorescent measurements in a purified in vitro
system, Lovell et al. (2008) simultaneously measured the rates
of three reactions leading to pore formation and determined
the following order of events. First tBid binds rapidly to mito-
chondrial membranes where tBid and Bax interact, promoting
insertion of Bax into the membrane, a rate-limiting step. Bax
then oligomerizes to form pores, and membranes become
permeable. In vitro, Bax oligomerization continues even after
membranes are permeabilized (Lovell et al., 2008). In cell culture,
Bax multimerization is first detected immediately prior to MOMP
and then continues for at least 30 min, ultimately generating
many more Bax puncta or pores than the number required for
MOMP (Albeck et al., 2008b; Dussmann et al., 2010). Formation
of the first observable Bax (or Bak) puncta correlates temporally
and spatially with the first subset of mitochondria to undergo
MOMP. Pore formation and MOMP then spread through the
cell as a wave with a velocity of 0.6 mm/s, a process that has
been modeled using a PDE network (Rehm et al., 2009). The
process of pore formation proceedsmore rapidly at higher doses
of TRAIL, presumably due to an increased rate of procaspase-8
activation (Rehm et al., 2009). However, it has recently been
observed that in a subset of HeLa cells, MCF-7 cells, and murine
embryonic fibroblasts, some mitochondria fail to undergo
MOMP in response to diverse proapoptotic stimuli (actinomycin
D, UV, staurosporine, or TNF). The subset of mitochondria that
remain intact fail to accumulate GFP-Bax puncta but undergo
complete MOMP when treated with the Bcl-2 antagonist and
investigational therapeutic ABT-737, suggesting that resistance
of mitochondria to MOMP lies at the point of Bax/Bak activation
(Tait et al., 2010). These findings suggest that mitochondria in
a single cell differ from each other with respect to their sensitiv-
ities to proapoptotic stimuli and that MOMPmight not always be
an all-or-none event at the single-cell level (Tait et al., 2010).
Time-lapse imaging of initiator caspase and MOMP reporters
shows that the height of the MOMP threshold varies from cell to
cell. MOMP is triggered following cleavage of10%of a reporter
carrying one IETD recognition site (Hellwig et al., 2008, 2010) orCell 144, March 18, 2011 ª2011 Elsevier Inc. 933
30%–60% of a reporter carrying two recognition sites (Albeck
et al., 2008a, 2008b; Spencer et al., 2009). Variation in the height
of the MOMP threshold from cell to cell (presumably arising from
variation in the levels of Bcl-2-family proteins, see below) can
most easily be resolved using the sensitized dual-IETD reporter
(Figure 2C) and contributes 20% of the total variability in the
time of death among HeLa cells in clonal population exposed
to 10 ng/ml TRAIL (Spencer et al., 2009). The remaining 80%
of the variability appears to reflect differences in the rate of Bid
cleavage, although these percentages are expected to change
with stimulus and cell type. However, the precise dynamics of
Bid cleavage have recently been thrown into some doubt:
a FRET reporter containing full-length Bid rather than an artificial
IETD caspase recognition site exhibits minimal cleavage prior to
MOMP (Hellwig et al., 2010). One explanation for this discrep-
ancy is that IETD-only reporters might be overly sensitive and
not reflect the kinetics of endogenous substrate cleavage. In
this view, cleavage of Bid by initiator caspases is subject to addi-
tional forms of regulation so that tBid does not accumulate until
just before MOMP (Hellwig et al., 2010). Conversely, the Bid-
containing FRET reporter might simply be insufficiently sensitive,
and levels of tBid required for MOMP (estimated to be <3% of
the total Bid pool) might be below the level of detection. In this
view, IETD-only reporters conveniently amplify a signal that
would otherwise be undetectable. Resolving this question will
require careful comparison of reporter constructs with endoge-
nous proteins, which will itself depend on the availability of anti-
bodies that can distinguish different caspase-8 substrates. It
seems likely that carefully calibrated models will also help with
data integration.
The rate at which initiator caspase substrates are cleaved
varies from cell to cell (Figure 2C). The current view is that the
strength of receptor signaling and the amount of active DISC
control the rate of initiator caspase substrate cleavage and
thus the rate of approach to the MOMP threshold, with lower
levels of prodeath stimulus leading to slower Bid cleavage and
slower onset of apoptosis. Models of DISC formation in FasL-
treated cells have questioned whether apoptosis simply slows
down with decreasing ligand concentrations (a continuous
decrease), or whether there is a minimum ligand:receptor ratio
needed for induction of apoptosis (a threshold; Bentele et al.,
2004). Modeling predicted that below a critical ligand:receptor
ratio of 1:100, apoptosis is completely blocked due to the
presence of the inhibitory DISC component c-FLIP. Above the
critical threshold, c-FLIP is insufficient to block all DISC activity
prior to the formation of active caspase-8. A follow-up study
refined this view by showing that active DISC is formed
at concentrations of a receptor crosslinking antibody (anti-
APO-1, which activates Fas receptors) below a critical threshold.
However, because c-FLIP has a higher affinity than procaspase-
8 to the few DISCs that are formed, activation of caspase-8 is
effectively inhibited (Lavrik et al., 2007). Continuing this line of
reasoning, Fricker et al. (2010) used modeling, biochemical
assays, and live-cell imaging to explore how levels of c-FLIP iso-
forms determine sensitivity to Fas signaling. Although c-FLIPS/R
is well established as an inhibitor of Fas-mediated apoptosis,
the role of c-FLIPL has been controversial because it plays both
pro- and antiapoptotic roles depending on expression level.934 Cell 144, March 18, 2011 ª2011 Elsevier Inc.Model analysis suggested that the effects of c-FLIPL on activa-
tion of procaspase-8 varywith FasL levels: relative to cells having
endogenous levels of c-FLIPL, 20-fold overexpression of c-FLIPL
blocks cell death when FasL levels are low but accelerates death
when FasL levels are high. However, even at high FasL levels,
a further increase in c-FLIPL concentration inhibits procaspase-
8 processing and decreases the extent of cell death. Models
can be quite helpful in exploring these sorts of quantitative rela-
tionships. One explanation supported bymodel analysis involves
the fact that c-FLIPL has higher affinity for DISCs than procas-
pase-8 but that procaspase-8 is present in cells in substantial
molar excess. At low FasL levels, few DISCs are formed, relative
affinities dominate, and the ratio of c-FLIPL to caspase-8 at
DISCs is high. At high levels of FasL, many DISCs are formed,
and the small number of c-FLIPL molecules (300 per HeLa
cell) is exhausted, allowing DISC-bound procaspase-8 to over-
whelm c-FLIPL. Thus, subtle changes in the levels of c-FLIPL
and FasL can change the timing and probability of death in
nonlinear ways that can be understood only if the concentrations
of interacting proteins are taken into account (Fricker et al., 2010).
An additional factor affecting the life-or-death fate of a cell
exposed to death ligand is the interplay between prosurvival
and proapoptotic pathways. The relative strength of these
competing regulatory processes is also thought to be
controlled by the composition of the DISC. Induced survival
signaling has been largely attributed to NF-kB, and many nega-
tive regulators of apoptosis are known to be induced by NF-kB,
including c-FLIP, BclxL, and members of the IAP family
(Gonzalvez and Ashkenazi, 2010). It is not yet clear which of
these factors is most important nor whether NF-kB-indepen-
dent processes, such as MAPK signaling, also play important
prosurvival functions. Whereas Bentele et al. (2004) and Fricker
et al. (2010) focused on the presence or absence of prodeath
signaling at the DISC, Lavrik et al. (2007) and Neumann et al.
(2010) explicitly focused on the balance between prodeath
versus prosurvival activities. Lavrik et al. (2007) demonstrated
that Erk kinase is activated in response to anti-APO-1 over
a wide range of doses, even in the presence of a pan-caspase
inhibitor. This work showed that survival signaling occurred in
parallel with death signaling, but it was not clear how the
survival signal was initiated. Neumann et al. (2010) built and
tested an ODE model of Fas-mediated apoptosis with a postu-
lated link between apoptosis and survival pathways in which
c-FLIPL is cleaved by caspase-8 into p43-FLIP, which binds
and activates IkB kinase (IKK). IKK then phosphorylates and
inhibits IkB, a negative regulator of NF-kB, leading to induction
of NF-kB-mediated transcription. Simulation and experiments
suggested that both proapoptotic (caspase-8 dependent) and
prosurvival (NF-kB-dependent) pathways are activated in
parallel and that a subtle balance between c-FLIPL and initiator
caspase levels determines which one predominates. By visual-
izing the levels of c-FLIPL and procaspase-8 on a parameter
landscape (Figure 3F), the authors showed that c-FLIPL can
disable, promote, or inhibit NF-kB activation depending on
whether the level of c-FLIPL is low, intermediate, or high. This
effect arises because high levels of c-FLIPL prevent caspase-
8-mediated processing of c-FLIPL into the IKK-binding p43-
FLIP form (Neumann et al., 2010).
Future work on the topic of induced survival signaling would
benefit from single-cell measurements combining reporters for
NF-kB target gene expression (Nelson et al., 2004) and reporters
of initiator caspase activity so as to capture feedback. Both the
apoptosis and the NF-kB fields have a tradition of utilizing live-
cell imaging and mathematical modeling (e.g., Ashall et al.,
2009; Hoffmann et al., 2002; Lee et al., 2009), and it would be
valuable to combine models of both processes. This would
lead to better understanding of competing prosurvival and pro-
death death processes in different cell types.
Cell-to-Cell Variation in the Timing of Apoptosis
Individual cells differ widely in their responses to apoptotic
stimuli (Figure 2D). Potential sources of cell-to-cell variability in
the timing and probability of apoptosis include genetic or epige-
netic differences, differences in cell-cycle phase, stochastic fluc-
tuations in biochemical reactions, and natural variation in protein
concentrations. To distinguish among these possibilities, three
independent groups followed dividing cells using time-lapse
microscopy and compared the timing and probability of
apoptosis in sister cells and in randomly selected pairs of cells
(Bhola and Simon, 2009; Rehm et al., 2009; Spencer et al.,
2009). At a dose of TRAIL sufficient to induce apoptosis in half
of the cells, the probability of death was observed to be highly
correlated between sisters, as was the time at which cells died.
Correlation in death time among sister cells has been observed
in a variety of cell types (HeLa, MCF-10A, NIH 3T3, HT1080,
andmurine embryonic fibroblasts) following exposure to a variety
of apoptosis-inducing agents (TRAIL, TNF-a, staurosporine, and
etoposide). In contrast, randomly selected cells were found to be
uncorrelated, and no obvious correlation with cell-cycle phase or
with position in the dish could be detected (Bhola and Simon,
2009; Spencer et al., 2009), although the way in which these
experiments were performed does not rule out some contribu-
tion from cell-cycle state (Rehm et al., 2009). Importantly, the
degree of similarity between sisters fell as the time since cell divi-
sion increased so that within one to two generations, sisters were
no more correlated than randomly chosen pairs of cells. This
transient heritability in timing of death argues against a genetic
or epigenetic explanation for cell-to-cell variability in apoptosis,
as genetic and epigenetic differences tend to be stable over
much longer timescales. The initial correlation between sister
cells also rules out a significant role for stochasticity in the reac-
tions that regulate caspase activation, a conclusion supported
by simulation (Eissing et al., 2005). Transient heritability in the
timing and probability of death data are most consistent with
an explanation rooted in natural cell-to-cell variation in the levels
or activities of proteins among genetically identical cells. Sister
cells are known to inherit similar levels of relatively abundant
biomolecules during cytokinesis, but levels then diverge due to
random fluctuations in protein synthesis and degradation (Sigal
et al., 2006). In support of this, experiments with cycloheximide
show that the rate of sister cell decorrelation is highly sensitive
to the rate of protein synthesis (Spencer et al., 2009).
Over the last decade, modeling and experimentation in
bacteria, yeast, and more recently in mammalian cells, have
provided a mechanistic framework for understanding stochastic
variation (‘‘noise’’) in rates of transcription and translation (Raj
and van Oudenaarden, 2008). The number of transcriptional initi-ation complexes on any single gene is small (potentially as small
as 1–2), and the probability that a transcript will be created in any
time interval is therefore highly stochastic. Fluctuations in mRNA
levels result in fluctuating rates of protein synthesis. With short-
lived or low-copy-number proteins, this can cause large fluctua-
tions in protein levels, whereas with relatively abundant proteins,
such as those controlling apoptosis, the most significant effect is
that different cells contain different concentrations of each
protein, and thus unique proteomes. Current models predict
that the distribution of concentrations across a population of
cells should be long-tailed, following a log-normal or gamma
distribution (Friedman et al., 2006; Krishna et al., 2005). In the
case of proteins controlling apoptosis, flow cytometry reveals
a nearly log-normal distribution with a coefficient of variation
(CV; a unit-less measure of variability equal to the standard devi-
ation divided by themean) ranging from 0.2 to 0.3 (Spencer et al.,
2009). Such a spread results in cells in the top 5th percentile
having >2.53 higher protein expression compared to cells in
the bottom 5th percentile (Niepel et al., 2009). The question
then arises of whether such modest variation in protein levels
is sufficient to explain the observed variation in the timing of
cell death. Model-based simulation suggested that it is: when
the distribution of cell death times was computed for TRAIL-
induced apoptosis assuming log-normally distributed protein
concentrations, a close match was observed between the vari-
ability in simulation and experiment (Spencer et al., 2009). In
the absence of any simple experimental test, the match between
simulation and measurement increases our confidence in the
hypothesis that natural variation in the levels of apoptotic regula-
tors is responsible for variability in the time and probability of cell
death.
Is it possible to establish a direct link between the levels of any
single protein and the probability and timing of apoptosis? In
principle such a measurement could be made by fluorescently
tagging proteins of interest at the endogenous locus and then
relating their levels to time of death using live-cell microscopy.
However, mathematical modeling suggests that achieving
reasonable predictability over cell fate would require single-cell
measurement of many protein levels (as well as some posttrans-
lational modifications), a difficult task. Alternatively, simulation
suggests that predictability can be achieved by measuring the
rates of critical reactions, such as the processing of caspase-8
substrates. Because this rate depends on the levels of multiple
upstream proteins, measuring it is much more informative than
simply knowing protein levels (Spencer et al., 2009). This conclu-
sion implies a fundamental limit to our ability to predict cell fate
based on single-cell proteomics.
Conclusions and Future Prospects
Key goals for a combined model- and experiment-driven anal-
ysis of apoptosis are to understand how multiple cooperating
and competing signals are integrated to effectively execute
a binary death-survival decision, to determine why some
processes and proteins are important in one cell type and not
in another, and to predict the responses of cells to death ligands
and chemotherapy drugs. A review of the literature thus far
suggests that these goals remain largely unfulfilled. Skeptics
will argue that quantitative analysis can only add details toCell 144, March 18, 2011 ª2011 Elsevier Inc. 935
existing conceptual frameworks or that mathematical models
are too theoretical and too dependent on assumptions to be
useful (although drawing a pathway diagram may involve just
as many assumptions). A more generous and realistic assess-
ment would be that mechanistic modeling of apoptosis has
had an impact in motivating the collection and analysis of quan-
titative single-cell data, critically evaluating potential regulatory
mechanisms, and investigating the origins of cell-to-cell vari-
ability.
Technical Challenges
Addressing the long-term goals of quantitative, model-driven
biology will require major conceptual and technical advances.
Most computational tools currently in use have been adapted
from other fields, but understanding a biological system is
nothing like fixing a radio. Cells are not well-mixed systems as
encountered in chemistry, nor are they easily understood in
terms of fundamental physical laws or obviously subject to the
design principles (such as modularity) encountered in engi-
neered systems. They resemble all of these to some extent,
but systems biology is currently immersed in the uncharted
process of working out which concepts from chemistry, physics,
and engineering are most useful in understanding cells and
tissues.
It is already evident that different research groups will
continue to build models differing in scope and level of detail
and customized to the biological questions being addressed.
Current approaches to model building typically involve de
novo creation of complex sets of equations in each paper.
A lack of transparency in the underlying assumptions makes it
difficult for practitioners, nevermind the general research
community, to understand how models differ from each other.
Fortunately, ‘‘rules-based’’ modeling methods now in develop-
ment promise to address the issue of model reusability and intel-
ligibility (Faeder et al., 2009; Hlavacek et al., 2006). More
rigorous means for linking models to experimental data and for
understanding which aspects of a model are supported by
data are required. Progress in this area is slow, but the basic
principles are understood in the context of engineering and
the physical sciences (Jaqaman and Danuser, 2006). Finally,
we must work to ensure basic familiarity with dynamical systems
among trainees. It is widely accepted that a working knowledge
of statistical methods such as clustering and regression is
essential in contemporary biomedicine, but it is unfortunate
that few students are taught that familiar Michaelis-Menten
equations are simply approximations to a mass-action
formalism written as networks of ODEs (Chen et al., 2010).
Biological Challenges
Cancer pharmacology is the area of translational medicine in
which models of apoptosis are most obviously of value. Critical
questions in the development of rational and personalized treat-
ment of cancer involve understanding precisely how anticancer
drugs induce apoptosis, why the extent of cell killing varies so
dramatically from one tumor to the next, and how we can predict
response to chemotherapy, both ‘‘targeted’’ and cytotoxic.
As yet no quantitative, model-based studies of these issues
have been reported, but it seems almost certain that sensitivity
and resistance will be controlled in a multifactorial manner.
Genes and proteins that are important in one cellular setting936 Cell 144, March 18, 2011 ª2011 Elsevier Inc.will not be significant in another. In the case of TRAIL, for
example, conventional molecular approaches have implicated
the levels of O-glycosylation enzymes (GALNT3, GALNT14;
(Wagner et al., 2007), TRAIL decoy receptors (DcR1, DcR2,
and osteoprotegerin), c-FLIP, BclxL, and inhibitor of apoptosis
proteins (IAPs) in TRAIL resistance in different cell lines (reviewed
in Zhang and Fang, 2005). It is likely that all of these explanations
are correct to some degree, and the key task therefore becomes
understanding the role of context. This is precisely wheremodels
hold great promise, as they are able to quantify and weigh the
contributions of multiple factors. Such context sensitivity could
be implemented by using a model in which the topology and
rate constants remain the same for all cell types but protein
concentrations (initial conditions) are altered to match experi-
mentally measured protein levels.
Ultimately, we need to understand the regulation of apoptosis
in the context of real human tissues and tumors. Because mech-
anistic modeling is dependent on quantitative, multiplex data,
this will not be straightforward, even in model organisms. New
in vivo caspase activity probes (Edgington et al., 2009) and
high-resolution intravital microscopy (Condeelis andWeissleder,
2010) will play an important role in data acquisition in vivo, but it
also seems probable that the development of mechanistic
models able to store, simulate, and rationalize results obtained
across a panel of cancer cell lines will be essential. Such
context-sensitive modeling might uncover a multifactorial
measurement that could be made on real human tumors.
Expression profiling and cancer genome sequencing also aspire
to personalize cancer therapy, but the framework we envision is
complementary in focusing on biochemical mechanism. A multi-
plex measurement method (BH3 profiling) already exists to
estimate the propensity of cells to undergo apoptosis; it involves
permeabilizing cells and then monitoring their responses to
diverse BH3-only peptides (Deng et al., 2007). BH3 profiling
can predict sensitivity to conventional chemotherapies and to
the Bcl-2/BclxL antagonist ABT-737 (Deng et al., 2007). It would
be valuable to construct a predictive mathematical framework
for BH3 profiling and thereby generate precise mechanistic
understanding of drug sensitivity and resistance that could be
translated clinically.
Single-cell analysis of cellular responses to FasL and TRAIL
has highlighted the dramatic impact of cell-to-cell variability in
determining the timing and probability of response. That cells
surviving exposure to a death ligand or cytotoxic drug can
resume normal proliferation is a testament to the ‘‘stiff trigger,’’
‘‘all-or-nothing’’ nature of the apoptotic switch. Cells that cross
the threshold for MOMP are normally fully committed to die,
whereas cells that remain below it can recover and continue to
proliferate. In the case of receptor-mediated apoptosis, the
presence of a dose-dependent variable delay preceding
MOMP followed by a dose-independent and nearly invariant
post-MOMP period likely reflects the evolutionary advantages
of such a system. Variability in the timing and probability of
apoptosis makes it possible for a uniform population of cells to
respond to a prodeath stimulus in a gradedmanner, even though
the response is binary at the single-cell level. In contrast, by
undergoing MOMP and effector caspase activation in a rapid
and invariant way, cells avoid the highly deleterious effects of
initiating but not completing apoptosis; these effects include
formation of ‘‘undead’’ cells with damaged genomes.
Variability in response appears to be universal across diverse
cell lines and proapoptotic stimuli (Cohen et al., 2008; Gascoigne
and Taylor, 2008; Geva-Zatorsky et al., 2006; Orth et al., 2008;
Sharma et al., 2010; Spencer et al., 2009; Huang et al., 2010).
For example, Gascoigne and Taylor (2008) characterized the
response of 15 cell lines to three different classes of antimitotic
drugs and found significant inter- and intra-cell line variation,
with cells exhibiting multiple distinct phenotypes in response to
the same treatment. Cohen et al. (2008) correlated variability in
the levels of two proteins with the life-or-death response to the
cancer drug camptothecin. Most recently, Sharma et al. (2010)
detected a small subpopulation of reversibly ‘‘drug-tolerant’’
cells following treatment with cisplatin or the epidermal growth
factor receptor inhibitor erlotinib. The significance of these find-
ings is that cancer therapy is beset by the problem of fractional,
or incomplete, killing of tumor cells. Multiple explanations have
been proposed for fractional killing, including drug insensitivity
during certain phases of the cell cycle, genetic heterogeneity,
incomplete access of tumor to drug (Chabner and Longo,
2006; Skeel, 2003), and the existence of drug-resistant cancer
stem cells (Reya et al., 2001). Single-cell imaging and computa-
tional modeling of apoptosis have added to this list cell-to-cell
variability in protein levels arising from stochasticity in protein
expression (Spencer et al., 2009). A critical task for the future
will be to ascertain the relative importance of these processes
in determining the extent of fractional killing with real tumors
and therapeutic protocols. Because a wide variety of biochem-
ical processes are involved, all operating on different timescales,
developing an appropriate quantitative framework will be a key
step to better understanding.
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